Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ.
Standard
Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ. / Sänger, Nicole; Harms-Effenberger, Katharina; Riethdorf, Sabine; Viviane, Van Haasteren; Gauwerky, Johannes; Wiegratz, Inka; Strebhardt, Klaus; Kaufmann, Manfred; Pantel, Klaus.
In: INT J CANCER, Vol. 129, No. 10, 10, 2011, p. 2522-2526.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ.
AU - Sänger, Nicole
AU - Harms-Effenberger, Katharina
AU - Riethdorf, Sabine
AU - Viviane, Van Haasteren
AU - Gauwerky, Johannes
AU - Wiegratz, Inka
AU - Strebhardt, Klaus
AU - Kaufmann, Manfred
AU - Pantel, Klaus
PY - 2011
Y1 - 2011
N2 - Detection of disseminated tumor cells (DTCs) in bone marrow is an independent prognostic factor in primary breast cancer. Here, we conducted a proof-of-principle study to evaluate whether this tumor cell spread occurs already in patients with ductal carcinoma in situ (DCIS). After preoperative screening by stereotactic core biopsy, 30 consecutive women with DCIS were included. Bone marrow aspirates, taken at the time of primary surgery, were subjected to DTC detection by a standardized immunoassay using the established monoclonal anti-cytokeratin antibodies A45-B/B3 and AE1/AE3. DTCs were detected in 4 of 19 cases of pure DCIS (21.1%) and in four of seven cases of DCIS with microinvasion (57.1%). After a median follow-up time of 22 months, two initially DTC-positive patients suffered from contralateral carcinoma and contralateral DCIS at months 12 and 30, respectively, whereas the remaining patients were relapse free. Thus, hematogenous tumor cell dissemination into bone marrow is an early event in breast cancer development.
AB - Detection of disseminated tumor cells (DTCs) in bone marrow is an independent prognostic factor in primary breast cancer. Here, we conducted a proof-of-principle study to evaluate whether this tumor cell spread occurs already in patients with ductal carcinoma in situ (DCIS). After preoperative screening by stereotactic core biopsy, 30 consecutive women with DCIS were included. Bone marrow aspirates, taken at the time of primary surgery, were subjected to DTC detection by a standardized immunoassay using the established monoclonal anti-cytokeratin antibodies A45-B/B3 and AE1/AE3. DTCs were detected in 4 of 19 cases of pure DCIS (21.1%) and in four of seven cases of DCIS with microinvasion (57.1%). After a median follow-up time of 22 months, two initially DTC-positive patients suffered from contralateral carcinoma and contralateral DCIS at months 12 and 30, respectively, whereas the remaining patients were relapse free. Thus, hematogenous tumor cell dissemination into bone marrow is an early event in breast cancer development.
KW - Adult
KW - Humans
KW - Aged
KW - Female
KW - Middle Aged
KW - Prognosis
KW - Bone Marrow/pathology
KW - Breast Neoplasms/pathology
KW - Carcinoma, Intraductal, Noninfiltrating/pathology
KW - Neoplastic Cells, Circulating/pathology
KW - Adult
KW - Humans
KW - Aged
KW - Female
KW - Middle Aged
KW - Prognosis
KW - Bone Marrow/pathology
KW - Breast Neoplasms/pathology
KW - Carcinoma, Intraductal, Noninfiltrating/pathology
KW - Neoplastic Cells, Circulating/pathology
M3 - SCORING: Journal article
VL - 129
SP - 2522
EP - 2526
JO - INT J CANCER
JF - INT J CANCER
SN - 0020-7136
IS - 10
M1 - 10
ER -
